Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections
Recruitment status was Recruiting
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections|
- Eradication of infection [ Time Frame: One year ] [ Designated as safety issue: No ]Success will be defined as those patients whose implant is still in place at one year and demonstrate no clinical signs or symptoms of infection. Eradication of infection will be defined as those patients whose inflammatory markers (ESR and CRP)have returned to normal values following one year treatment.
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||September 2014|
|Estimated Primary Completion Date:||September 2014 (Final data collection date for primary outcome measure)|
No Intervention: No Collatamp sponge
Joint infection treated without the use of the Collatamp G sponge.
Experimental: Collatamp G sponge
Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
Drug: Collatamp G sponge
Collatamp G is an antibiotic impregnated sponge
Other Name: Gentamicin Sulphate 2.0 mg/cm2
While total hip and knee replacement surgery remains a highly successful treatment for arthritis of the hip and knee, infection following a joint replacement still remains an issue, occurring in approximately 1-2% of joint replacement patients. Treatment of infection remains very difficult with the successful elimination of the infection being quite variable, ranging from as low as 10% to approximately 85-90%, following a two stage revision. A two stage revision involves removing the joint replacement implant and replacing it with a cement spacer until the surgeon is comfortable that the infection has been eliminated. In the second part of a two stage revision the cement spacer is removed and a new joint replacement implant is inserted in the joint space. In particular, the treatment of an acute infection, that is, infection occurring in the early postoperative period or in a patient with less than two weeks duration of symptoms, is particularly problematic. As a first line of treatment, surgeons often perform an irrigation (washing out a wound with a stream of water) and debridement (the surgical removal of contaminated tissue) surrounding the joint in the hopes of preserving the joint replacement, although the success rate is highly variable. Most treatment routines involve irrigation of the joint with copious (large) amounts of fluid, removal of infected soft tissue, replacement of any removable parts (example plastic liners or femoral heads) and then intravenous antibiotics for a prolonged period of time (6-8 weeks). It is thought that part of the reason for failure with this form of treatment is the inability to adequately provide local antibiotics to the joint environment while the joint replacement components are in place. In particular, the formation of a bacterial slime by the infecting organism, which can attach itself to the metallic components, is thought to be a major hindrance to removing infection. In theory, the ability to infuse local antibiotics to the joint could prove advantageous to the treatment of joint replacement infections.
Collatamp® is a like a small flat sponge soaked with antibiotics that delivers a consistent dose of fast-release antibiotics called Gentamicin Sulphate (2.0 mg/cm2). The antibiotic is concentrated locally in the tissue around the joint replacement. The sponge is reabsorbed by the body and therefore does not need to be surgically removed. Collatamp® sponges have been utilized in the clinical setting for over 20 yrs. This material has been used in treatment of other orthopaedic, general surgery, and cardiac infections, but has not been studied in the setting of infected total joint replacements. The purpose of this study is to examine the use of CollatampTM sponges as an addition to the treatment of acute joint infections after a total joint replacement surgery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01667874
|Contact: Abigail E Korczak, BScN||(519) 685-8300 ext 32789||Abigail.Korczak@lhsc.on.ca|
|London Health Sciences Centre||Recruiting|
|London, Ontario, Canada, N6A 5A5|
|Contact: Abigail Korczak, BScN 5196858300 ext 32789 firstname.lastname@example.org|
|Sub-Investigator: Steven J MacDonald, MD, FRCSC|
|Sub-Investigator: James Howard, MD, FRCSC|
|Sub-Investigator: Douglas Naudie, MD, FRCSC|
|Sub-Investigator: James McAuley, MD, FRCSC|
|Principal Investigator:||Richard McCalden, MD, MPhil(Edin), F.R.C.S.(C)||London Health Sciences Centre - University Hospital|